Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Investment securities available for sale, amortized cost		$ 341,011	$ 333,950
Loans receivable, allowance for credit losses	[1]	$ 21,970	$ 17,510
Preferred stock, par value (in dollars per share)		$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)		5,000,000	5,000,000
Preferred stock, shares issued (in shares)		0	0
Preferred stock, shares outstanding (in shares)		0	0
Common stock, par value (in dollars per share)		$ 0.01	$ 0.01
Common stock, shares authorized (in shares)		75,000,000	75,000,000
Common stock, shares issued (in shares)		9,365,979	9,611,876
Common stock, shares outstanding (in shares)		9,365,979	9,611,876

[1] Allowance for credit losses on loans in 2023 reported using the CECL method and in 2022 reported using the incurred loss method.